Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

NetScientific appoints Prof. Stephen Smith as NED

17 Feb 2016 07:00

RNS Number : 2646P
NetScientific PLC
17 February 2016
 

NetScientific plc

 

NetScientific appoints Professor Stephen Smith as Non-Executive Director

 

London, UK - 17 February 2016 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints Professor Stephen Smith as Non-Executive Director, with effect from today. Professor Smith will also join both the audit and remuneration committees.

Stephen has held senior leadership roles in the NHS and academia. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO with the Medical Research Council, University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust.

He was responsible for the largest merger in the NHS, the creation of the UK's first Academic Health Science Centre in 2007. The merger brought together four London based NHS Trusts and ultimately led to the creation of Imperial College Healthcare NHS Trust, where Stephen served for four years as the first CEO. He also retained his position as Dean of the Faculty of Medicine at Imperial College, London and was responsible for facilitating the commercialisation of life sciences and healthcare.

During his career, Stephen has spun two companies out of Cambridge - Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.

Stephen has extensive non-executive experience serving on the Boards of the National Healthcare Group Singapore which developed integrated care through nine polyclinics. In Australia, he was on the Board of the Royal Melbourne Hospital and the Victorian Comprehensive Cancer Centre, a $1billion project to create a fully integrated cancer care facility that brings together an integrated research, service and education offering to four million patients in Victoria.

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific said: "Stephen's impressive leadership experience in mergers and commercialisation internationally further strengthens the Group. We look forward to welcoming Stephen to the team as we continue to build our subsidiary companies towards developing new technologies and concepts in healthcare management and diagnostics to improve patient care and outcomes."

 

Other than the information provided below, which is being disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies, there is no further information required to be disclosed pursuant to this rule. Stephen Kevin Smith, aged 64 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

Past Directorships

StephenKSmith Ltd

London Genetics Limited

GNI (UK) Limited

The Nuffield Trust for Research and Policy Studies in Health Services

Metris Therapeutics Limited

 

I C Consultants Limited

 

 

- Ends -

 

Contact Details

 

NetScientific

François R. Martelet, M.D., CEO

 

 

Tel: +44 (0)20 3514 1800

 Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

 

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net. 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADGGDDXGBBGLL
Date   Source Headline
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract
1st Nov 20212:16 pmRNSPDS to License Novel Proteins for Flu Vaccine
26th Oct 20217:00 amRNSEMV Capital Participates in £843k Sofant Funding
22nd Oct 202111:18 amRNSProAxsis announces the approval of a key US patent
22nd Oct 20219:04 amRNSHolding(s) in Company
21st Oct 20214:40 pmRNSSecond Price Monitoring Extn
21st Oct 20214:35 pmRNSPrice Monitoring Extension
21st Oct 20212:17 pmRNSPDS Phase 2 Clinical Trial Update
5th Oct 20217:00 amRNSPDS Phase 2 Clinical Trial Update
4th Oct 20217:00 amRNSInvestor Presentations
30th Sep 202110:22 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSGrant of Options to Directors
29th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Analyst Briefing
16th Sep 20217:00 amRNSInvestment in Martlet Capital Limited
9th Aug 20215:59 pmRNSHolding(s) in Company
30th Jul 20219:12 amRNSHolding(s) in Company
26th Jul 20214:25 pmRNSHolding(s) in Company
22nd Jul 20214:29 pmRNSHolding(s) in Company
20th Jul 20212:05 pmRNSSecond Price Monitoring Extn
20th Jul 20212:00 pmRNSPrice Monitoring Extension
16th Jul 202110:35 amRNSDirector/PDMR Shareholding
1st Jul 202112:08 pmRNSHolding(s) in Company
30th Jun 20213:42 pmRNSHolding(s) in Company
30th Jun 202110:29 amRNSHolding(s) in Company
30th Jun 202110:27 amRNSHolding(s) in Company
28th Jun 20213:18 pmRNSResult of General Meeting, TVR & PDMR Dealings
22nd Jun 20217:00 amRNSPDS Announces Closing of c. $52m Public Offering
16th Jun 20217:00 amRNSNSCI Participates in $45m PDS Equity Issue
15th Jun 20217:00 amRNSPDS announces proposed offering of common stock
10th Jun 202112:56 pmRNSResult of Placing and Total Voting Rights
10th Jun 20217:00 amRNSProposed Placing
9th Jun 20214:40 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.